Abstract Number: 050 • 2020 Pediatric Rheumatology Symposium
Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre
Background/Purpose: The use of biologic response modifiers(BRMs) is associated with an increased risk of infections.We also use biosimilars for two reasons:1. originator not available, like…Abstract Number: 1221 • 2018 ACR/ARHP Annual Meeting
Serologic Screening for Coccidioidomycosis Among Medicare Beneficiaries with Rheumatic Diseases on Biologic Response Modifiers, Corticosteroids, and Dmards
Background/Purpose: The 2016 Infectious Disease Society of America (IDSA) guidelines recommend serologic screening for coccidioidomycosis (Cocci) prior to initiation of biologic response modifiers (BRMs). Current…Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting
Real World IGRA Testing in Rheumatology Practice
Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting
Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting
Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…Abstract Number: 649 • 2016 ACR/ARHP Annual Meeting
Clinical Evaluation Usefulness of Standardized Protocol Strategies of Dose Reduction in Patients with Rheumatoid Arthritis in Clinical Remission Treated with Biologic Therapies. the Optibio Study
Background/Purpose: The OPTIBIO study is a clinical trial whose primary endpoint is to evaluate the proportion of patients that after one year are maintained in…Abstract Number: 1350 • 2016 ACR/ARHP Annual Meeting
Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease: 8 Years of Experience
Background/Purpose: Coccidioidomycosis (valley fever) is an endemic fungal infection that typically causes a self-limited pulmonary illness in the Southwestern United States,. Immunosuppressed patients are at…Abstract Number: 2482 • 2016 ACR/ARHP Annual Meeting
Long Term Drug Survival of Adalimumab and Etanercept Treatment for Rheumatoid Arthritis with and without Methotrexate
Background/Purpose: Tumor necrosis factor alpha (TNF-α) inhibitors are effective, safe and widely used treatment for rheumatoid arthritis (RA). The therapy is often started in combination…Abstract Number: 2641 • 2016 ACR/ARHP Annual Meeting
Safety of Synthetic and Biological Dmards: Slr Informing the Update of the EULAR Recommendations for the Management of RA
Background/Purpose: As part of the update of the EULAR recommendations for the management of RA, we performed a systematic literature review to assess the safety…Abstract Number: 601 • 2015 ACR/ARHP Annual Meeting
Step-Down Strategy of Spacing TNF-Blockers Injections for Established Rheumatoid Arthritis in Remission: A within Randomized Control Trial Based Cost-Utility Analysis
Background/Purpose: Once remission is achieved for patients with rheumatoid arthritis (RA), treatment down-titration should be attempted, for safety issues or economic reasons. One of the…Abstract Number: 548 • 2015 ACR/ARHP Annual Meeting
Comparison of Dose Escalation and Co-Therapy Intensification Between Patients with Rheumatoid Arthritis Initiating Biologic Treatment with Etanercept, Adalimumab and Infliximab
Background/Purpose: The individual response to anti-TNFs etanercept (ETA), infliximab (INF) and adalimumab (ADA) in rheumatoid arthritis (RA) may vary. Options for managing inadequate response include…Abstract Number: 2205 • 2014 ACR/ARHP Annual Meeting
Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease
Background/Purpose: In the Southwestern United States, coccidioidomycosis (valley fever) is an endemic fungal infection which typically causes a self-limited pulmonary illness. Immunosuppressed patients, including those…Abstract Number: 2387 • 2013 ACR/ARHP Annual Meeting
Change of serum Amyloid a predict The Effect Of Biological Treatment In Rheumatoid Arthritis Patient
Background/Purpose: The C-reactive protein (CRP) level and the erythrocyte sedimentation rate (ESR) are common markers of inflammation in patients with rheumatoid arthritis (RA). The serum…Abstract Number: 382 • 2013 ACR/ARHP Annual Meeting
Effect Of Biologic Disease Modifiers On Cardiovascular Risk Of Patients With Rheumatoid Arthritis – 2 Years Prospective Cohort Study
Background/Purpose: People with RA have a higher risk for developing cardiovascular diseases than the general population. The pathogenic mechanisms in RA appear to be complex…Abstract Number: 368 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept-Methotrexate Therapy On Patient-Reported Outcomes in Rheumatoid Arthritis Patients with up to 12 Months of Symptoms
Background/Purpose: Patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA) are critical in evaluating RA treatment effects on function and health-related quality of life (HR-QoL).…
ACR Meeting Abstracts